What is Métoclopramide?
Métoclopramide is used to treat the symptoms of a certain type of stomach problem called gastroparesis in patients with diabetes. It works by increasing the movements or contractions of the stomach and intestines. It relieves symptoms such as nausea, vomiting, heartburn, a feeling of fullness after meals, and loss of appetite. Métoclopramide is also used to treat heartburn for patients with gastroesophageal reflux disease (GERD). GERD is esophageal irritation from the backward flow of gastric acid into the esophagus.
Métoclopramide is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Métoclopramide is used in certain patients with the following medical conditions:
- Failure of the stomach to empty its contents.
- Nausea and vomiting caused by other medicines.
- Persistent hiccups.
- Prevention of aspirating fluid into the lungs during surgery.
- Vascular headaches.
Métoclopramide indications
Diabetic Gastroparesis (Diabetic Gastric Stasis)
Métoclopramide (Métoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.
The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy
Métoclopramide Injection (Métoclopramide injection) is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy.
The Prevention of Postoperative Nausea and Vomiting
Métoclopramide Injection (Métoclopramide injection) is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable.
Small Bowel Intubation
Métoclopramide Injection (Métoclopramide injection) may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers.
Radiological Examination
Métoclopramide Injection (Métoclopramide injection) may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine.
How should I use Métoclopramide?
Use Métoclopramide as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Métoclopramide comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Métoclopramide refilled.
- Take Métoclopramide by mouth 30 minutes before meals and at bedtime without food or water unless directed otherwise by your doctor.
- Do not remove the tablet from the blister pack until you are ready to take Métoclopramide. Make sure that your hands are dry when you open the blister pack. If the tablet breaks or crumbles while handling, discard and remove a new tablet. Place the tablet on your tongue. The tablet dissolves quickly and can be swallowed with saliva. Take the tablet immediately after opening the blister pack. Do not store the removed tablet for future use.
- It may take several days to weeks for Métoclopramide to work. Do not stop taking Métoclopramide without checking with your doctor.
- If you miss a dose of Métoclopramide, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Métoclopramide.
Uses of Métoclopramide in details
Use: Labeled Indications
Injection:
Chemotherapy-induced nausea and vomiting, prophylaxis: Prophylaxis of nausea and vomiting associated with emetogenic cancer chemotherapy. Note: Injectable Métoclopramide prior to moderate- to high-emetic-risk chemotherapy is rarely indicated due to the potential for neurologic events and availability of more efficacious alternative agents.
Gastroparesis, diabetic: Relief of symptoms associated with acute and recurrent diabetic gastric stasis.
Oral:
Gastroesophageal reflux disease (GERD), refractory: Short-term (4 to 12 weeks) treatment in adults with documented symptomatic GERD who fail to respond to conventional therapy.
Note: May use Métoclopramide as an adjunctive therapy only if gastroparesis is confirmed. The American College of Gastroenterology (ACG) guidelines for the treatment of GERD recommend that diagnostic evaluation to confirm underlying gastroparesis be performed prior to considering the use of prokinetic agents (ACG [Katz 2013]). Furthermore, American Gastroenterological Association (AGA) guidelines for the treatment of GERD recommend against the use of Métoclopramide as monotherapy or adjunctive therapy in patients with GERD (AGA [Kahrilas 2008]).
Gastroparesis, diabetic: Relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Off Label Uses
Aspiration prophylaxis in patients undergoing anesthesia
Data from multiple studies of varying methodologies (including randomized, double-blind, placebo-controlled trials) support the use of Métoclopramide for the prevention of aspiration in patients undergoing anesthesia, for the treatment of acute tension-type headaches in the emergency department setting.
Métoclopramide description
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Métoclopramide also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Métoclopramide dosage
Usual Adult Métoclopramide Dose for Nausea/Vomiting:
Postoperative nausea and vomiting:
Parenteral: 10 to 20 mg IM at or near the end of surgery
Usual Adult Métoclopramide Dose for Gastroesophageal Reflux Disease:
Oral: 10 to 15 mg up to 4 times a day 30 minutes before meals and at bedtime, depending upon symptoms being treated and clinical response. Therapy should not exceed 12 weeks.
Usual Adult Métoclopramide Dose for Small Intestine Intubation:
If the tube has not passed the pylorus with conventional methods in 10 minutes, a single (undiluted) dose may be administered IV slowly over 1 to 2 minutes:
Adults and pediatric patients greater than or equal to 14 years: 10 mg IV as a single dose administered over 1 to 2 minutes.
Usual Adult Métoclopramide Dose for Radiographic Exam:
Adults and pediatric patients greater than or equal to 14 years: 10 mg IV as a single dose administered over 1 to 2 minutes to facilitate gastric emptying where delayed gastric emptying interferes with radiological examination of the stomach and/or small intestine.
Usual Adult Métoclopramide Dose for Gastroparesis:
During the earliest manifestations of diabetic gastric stasis, oral administration may be initiated. If severe symptoms are present, therapy should begin with IM or IV administration for up to 10 days until symptoms subside at which time the patient can be switched to oral therapy. Since diabetic gastric stasis is often recurrent, therapy should be reinstituted at the earliest manifestation.
Parenteral: 10 mg 4 times daily, IV (slowly over a 1 to 2 minute period) or IM for up to 10 days.
Oral: 10 mg 4 times daily, 30 minutes before meals and at bedtime, for 2 to 8 weeks depending on clinical response.
Usual Adult Métoclopramide Dose for Nausea/Vomiting -- Chemotherapy Induced:
IV infusion: 1 to 2 mg/kg/dose (depending on the emetogenic potential of the agent) IV (infused over a period of not less than 15 minutes) 30 minutes before administration of chemotherapy. The dose may be repeated twice at 2 hour intervals following the initial dose. If vomiting is still not suppressed, the same dose may be repeated 3 more times at 3 hour intervals.
For doses higher than 10 mg, the injection should be diluted in 50 mL of a parenteral solution. Normal saline is the preferred diluent.
If acute dystonic reactions occur, 50 mg of diphenhydramine hydrochloride may be injected IM.
Usual Adult Métoclopramide Dose for Migraine:
Use for treatment of migraine headaches is not an FDA approved indication; however, Métoclopramide has shown efficacy in studies at a dose of 10 to 20 mg IV once (used in combination with analgesics or ergot derivatives).
Usual Pediatric Métoclopramide Dose for Gastroesophageal Reflux Disease:
Métoclopramide is not approved by the FDA for gastroesophageal reflux disease in pediatric patients; however, the following doses have been studied:
Oral, IM, IV:
Infants and Children: 0.4 to 0.8 mg/kg/day in 4 divided doses
Usual Pediatric Métoclopramide Dose for Small Intestine Intubation:
Métoclopramide IV is approved by the FDA for pediatric use to facilitate small bowel intubation by causing gastric emptying where delayed gastric emptying interferes with radiological examination of the stomach and/or small intestine.
If the tube has not passed the pylorus with conventional methods in 10 minutes, a single (undiluted) dose may be administered IV slowly over 1 to 2 minutes:
Less than 6 years: 0.1 mg/kg IV as a single dose
6 to 14 years: 2.5 to 5 mg IV as a single dose
Children greater than 14 years: 10 mg as a single dose
Usual Pediatric Métoclopramide Dose for Nausea/Vomiting -- Chemotherapy Induced:
Métoclopramide is not approved by the FDA for chemotherapy induced nausea and vomiting in pediatric patients; however, the following doses have been studied:
IV:
1 to 2 mg/kg/dose IV every 30 minutes before chemotherapy and every 2 to 4 hours
Usual Pediatric Métoclopramide Dose for Nausea/Vomiting -- Postoperative:
Métoclopramide is not approved by the FDA for postoperative nausea and vomiting in pediatric patients; however, the following doses have been studied:
IV:
Children less than or equal to 14 years: 0.1 to 0.2 mg/kg/dose (maximum dose: 10 mg/dose); repeat every 6 to 8 hours as needed
Children greater than 14 years and Adults: 10 mg; repeat every 6 to 8 hours as needed
Métoclopramide interactions
See also:
What other drugs will affect Métoclopramide?
Anticholinergic Agents: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Monitor therapy
Anti-Parkinson Agents (Dopamine Agonist): Métoclopramide may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Monitor therapy
Antipsychotic Agents: Métoclopramide may enhance the adverse/toxic effect of Antipsychotic Agents. Avoid combination
Atovaquone: Métoclopramide may decrease the serum concentration of Atovaquone. Management: Consider alternatives to Métoclopramide when possible; atovaquone should only be used with Métoclopramide if no other antiemetics are available. Consider therapy modification
CycloSPORINE (Systemic): Métoclopramide may increase the absorption of CycloSPORINE (Systemic). Monitor therapy
CYP2D6 Inhibitors (Strong): May increase the serum concentration of Métoclopramide. Management: Reduce Métoclopramide dose to 5 mg 4 times daily (30 minutes before each meal and at bedtime) and limit the maximum daily dose to 20 mg if combined with strong CYP2D6 inhibitors. Consider therapy modification
Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Monitor therapy
Deutetrabenazine: May enhance the adverse/toxic effect of Métoclopramide. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased. Monitor therapy
Droperidol: May enhance the adverse/toxic effect of Métoclopramide. Avoid combination
Fosfomycin: Gastrointestinal Agents (Prokinetic) may decrease the serum concentration of Fosfomycin. Monitor therapy
Levosulpiride: Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. Monitor therapy
Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Monitor therapy
MetyroSINE: May enhance the adverse/toxic effect of Métoclopramide. Management: Seek alternatives to this combination when possible. Monitor patients receiving Métoclopramide with metyrosine for development of extrapyramidal symptoms. Consider therapy modification
Monoamine Oxidase Inhibitors: Métoclopramide may enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Avoid combination
Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy
Opioid Agonists: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Monitor therapy
Posaconazole: Métoclopramide may decrease the serum concentration of Posaconazole. Monitor therapy
Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Monitor therapy
Promethazine: Métoclopramide may enhance the adverse/toxic effect of Promethazine. Avoid combination
Quinagolide: Métoclopramide may diminish the therapeutic effect of Quinagolide. Monitor therapy
Rivastigmine: May enhance the adverse/toxic effect of Métoclopramide. Specifically, the risk of extrapyramidal adverse reactions may be increased with this combination. Avoid combination
Selective Serotonin Reuptake Inhibitors: Métoclopramide may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving Métoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome. Consider therapy modification
Serotonin/Norepinephrine Reuptake Inhibitors: Métoclopramide may enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving Métoclopramide with serotonin/norepinephrine reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome. Consider therapy modification
Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy
Tacrolimus (Systemic): Métoclopramide may increase the serum concentration of Tacrolimus (Systemic). Specifically, treatment of gastroparesis may increase tacrolimus concentrations. Monitor therapy
Tetrabenazine: Métoclopramide may enhance the adverse/toxic effect of Tetrabenazine. Avoid combination
Thiopental: Métoclopramide may enhance the therapeutic effect of Thiopental. Management: Consider thiopental dose reduction when used concomitantly with Métoclopramide. Monitor patient response to treatment closely if using this combination. Consider therapy modification
Tricyclic Antidepressants: Métoclopramide may enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving Métoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome. Consider therapy modification
Trimetazidine: Métoclopramide may enhance the adverse/toxic effect of Trimetazidine. Specifically, the risk of extrapyramidal symptoms may be enhanced. Avoid combination
Métoclopramide side effects
See also:
What are the possible side effects of Métoclopramide?
Applies to Métoclopramide: oral solution, oral syrup, oral tablet, oral tablet disintegrating
Other dosage forms:
- solution
In addition to its needed effects, some unwanted effects may be caused by Métoclopramide. In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Métoclopramide:
Rare
- Abdominal or stomach pain or tenderness
- chills
- clay colored stools
- convulsions (seizures)
- dark urine
- difficulty with breathing
- difficulty with speaking or swallowing
- dizziness or fainting
- fast or irregular heartbeat
- fever
- general feeling of tiredness or weakness
- headache (severe or continuing)
- inability to move the eyes
- increase in blood pressure
- increased sweating
- itching
- lip smacking or puckering
- loss of appetite
- loss of balance control
- loss of bladder control
- mask-like face
- muscle spasms of the face, neck, and back
- nausea and vomiting
- puffing of the cheeks
- rapid or worm-like movements of the tongue
- shuffling walk
- skin rash
- sore throat
- stiffness of the arms or legs
- swelling of the feet or lower legs
- tic-like or twitching movements
- trembling and shaking of the hands and fingers
- twisting movements of the body
- uncontrolled chewing movements
- uncontrolled movements of the arms and legs
- unusually pale skin
- weakness of the arms and legs
- yellow eyes or skin
If any of the following symptoms of overdose occur while taking Métoclopramide, get emergency help immediately:
Symptoms of overdose:
- Confusion
- drowsiness (severe)
Minor Side Effects
Some of the side effects that can occur with Métoclopramide may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
More common:
- Diarrhea
- drowsiness
- restlessness
- Breast tenderness and swelling
- changes in menstruation
- constipation
- decreased interest in sexual intercourse
- inability to have or keep an erection
- increased flow of breast milk
- increased need to urinate
- loss in sexual ability, desire, drive, or performance
- mental depression
- passing urine more often
- skin rash
- trouble sleeping
- unusual dryness of the mouth
- unusual irritability
Métoclopramide contraindications
See also:
What is the most important information I should know about Métoclopramide?
Métoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation.
Métoclopramide is contraindicated in patients with pheochro-mocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phen-tolamine.
Métoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug.
Métoclopramide should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.
Active ingredient matches for Métoclopramide:
Métoclopramide
| Unit description / dosage (Manufacturer) | Price, USD |
| Solution; Oral; Metoclopramide Hydrochloride 5 mg / 5 ml | |
| Tablet; Oral; Metoclopramide Hydrochloride 10 mg | |
| Tablet; Oral; Metoclopramide Hydrochloride 5 mg | |
| Injectable; Injection; Metoclopramide Hydrochloride 5 mg / ml | |
| Tablet; Oral; Metoclopramide 10 mg | |
| Tablet, Orally Disintegrating; Oral; Metoclopramide Hydrochloride 10 mg | |
| Tablet, Orally Disintegrating; Oral; Metoclopramide Hydrochloride 5 mg | |
| Metoclopramide hcl powder | $ 7.65 |
| Reglan 10 mg tablet | $ 1.81 |
| Reglan 5 mg tablet | $ 1.41 |
| Metoclopramide Hydrochloride 5 mg/ml | $ 1.39 |
| Reglan 5 mg/ml vial | $ 0.56 |
| Metoclopramide HCl 5 mg tablet | $ 0.43 |
| Metoclopramide 5 mg tablet | $ 0.33 |
| Metoclopramide 10 mg tablet | $ 0.28 |
| Metoclopramide 5 mg/ml ampul | $ 0.28 |
| Metoclopramide HCl 10 mg tablet | $ 0.27 |
| Metoclopramide HCl 5 mg/5ml Solution | $ 0.06 |
| Apo-Metoclop 10 mg Tablet | $ 0.06 |
| Apo-Metoclop 5 mg Tablet | $ 0.06 |
| Nu-Metoclopramide 10 mg Tablet | $ 0.06 |
| Nu-Metoclopramide 5 mg Tablet | $ 0.06 |
| Pms-Metoclopramide 10 mg Tablet | $ 0.06 |
| Pms-Metoclopramide 5 mg Tablet | $ 0.06 |
| Pms-Metoclopramide 1 mg/ml Liquid | $ 0.04 |
| Metoclopramide / Winston 5 mg | |
| Metoclopramide / Prince 5 mg/1 mL x 2 mL | |
| Metoclopramide / LITA 5 mg/1 mL x 2 mL | |
| Metoclopramide / Chin Teng 10 mg/1 g x 1 g | |
| Metoclopramide / Tai Yu 5 mg/1 mL x 2 mL | |
| Metoclopramide / Jen Sheng 7.67 mg | |
| Metoclopramide / Oriental 10 mg | |
| Metoclopramide / Update 3.84 mg | |
| Metoclopramide / Update 1 mg/1 mL x 1 mL | |
| Metoclopramide / Y.C. 10 mg | |
| Metoclopramide / C.I. 5 mg | |
| Metoclopramide / Jen Sheng 10 mg | |
| Metoclopramide / Update 5 mg | |
| Metoclopramide injection, solution 5 mg/mL (Cardinal Health (US)) | |
| Metoclopramide injection, solution 5 mg/2mL (General Injectables & Vaccines, Inc. (US)) | |
| Metoclopramide injection, solution 10 mg/2mL (General Injectables & Vaccines, Inc (US)) | |
| Metoclopramide solution 5 mg/5mL (Unit Dose Services (US)) | |
| Metoclopramide tablet 5 mg/1 (Qualitest Pharmaceuticals (US)) | |
| Metoclopramide tablet 10 mg/1 (Ranbaxy Pharmaceuticals Inc. (US)) | |
| Metoclopramide injection 5 mg/mL (Heritage Pharmaceuticals Inc. (US)) | |
| Metoclopramide solution 10 mg/10mL (Precision Dose Inc. (US)) | |
List of Métoclopramide substitutes (brand and generic names): | |
| Mygdalon (United Kingdom) | |
| N-Metoclopramid (Romania) | |
| Nadir (Italy) | |
| Nastifran (Turkey) | |
| Nauselon (Pakistan) | |
| NAUSHI DPS | |
| NAUSHI DPS Drops / 1mg per ml / 30ml units (Bestochem Formulations) | $ 0.27 |
| Nausigon (Austria) | |
| Nausil (Thailand) | |
| Nausil 10 mg x 500's (Siam Bheasach) | |
| Nausil 10 mg/2 mL x 100's (Siam Bheasach) | |
| Nausil inj 10 mg/2 mL 100 x 1's (Siam Bheasach) | |
| Nausil tab 10 mg 500's (Siam Bheasach) | |
| NAUSINORM | |
| NAUSINORM 5MG INJECTION 1 vial / 2 ML injection each (Unichem Laboratories Ltd) | $ 0.11 |
| Neolasil (Brazil) | |
| Neopramiel (Japan) | |
| Neu-Sensamide | |
| Nevomitan (Lithuania) | |
| Nilatika (Indonesia) | |
| Nilatika 10 mg x 10 x 10's (Nicholas) | $ 3.72 |
| No-Vomit (Brazil) | |
| Nofoklam (Indonesia) | |
| Nofoklam 10 mg x 10 x 10's (Nufarindo) | $ 3.12 |
| Norvin Plus | |
| Norvin Plus 500+5 Tablet (Pifer Pharmaceuticals Pvt Ltd) | $ 0.01 |
| Novomit (Argentina, Taiwan) | |
| Novomit 8 mg (Modgal Pharmaceuticals (P) Ltd.) | |
| Novomit 8 mg x Blister pk (Modgal Pharmaceuticals (P) Ltd.) | |
| Novomit 10+10 Tablet (Modgal Pharmaceuticals (P) Ltd.) | $ 0.06 |
| Novomit 4 mg Tablet (Modgal Pharmaceuticals (P) Ltd.) | $ 0.02 |
| NOVOMIT 10MG TABLET 1 strip / 10 tablets each (Modgal Pharmaceuticals (P) Ltd.) | $ 0.53 |
| NOVOMIT inj 2 mg x 1 mL x 2ml (Modgal Pharmaceuticals (P) Ltd.) | $ 0.26 |
| NOVOMIT tab 4 mg x 10's (Modgal Pharmaceuticals (P) Ltd.) | $ 0.24 |
| Novomit 10mg Tablet (Modgal Pharmaceuticals (P) Ltd.) | $ 0.05 |
| Nu-Metoclopramide | |
| Tablet; Oral; Metoclopramide Hydrochloride 10 mg | |
| Tablet; Oral; Metoclopramide Hydrochloride 5 mg | |
| Nutramid (Bangladesh) | |
| Octamide (United States) | |
| Opram (Indonesia) | |
| Opram 10 mg x 100's (Armoxindo Farma) | $ 8.00 |
| Opram 5 mg/5 mL x 60 mL x 1's (Armoxindo Farma) | $ 1.55 |
| Pancuron (Argentina, Brazil, South Korea) | |
| Pasperan 10 | |
| Paspertin (Austria, Germany, Switzerland) | |
| Drops; Oral; Metoclopramide Hydrochloride 4 mg / ml (Solvay) | |
| Injectable; Injection; Metoclopramide Hydrochloride 5 mg / ml (Solvay) | |
| Tablet, Film-Coated; Oral; Metoclopramide Hydrochloride (Solvay) | |
| Paspertin 10 mg (Austria, Switzerland) | |
| Paspertin 10mg/2ml (Switzerland) | |
| Peraprin (Japan) | |
See 1153 substitutes for Métoclopramide | |
References
- PubChem. "metoclopramide". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "metoclopramide". http://www.drugbank.ca/drugs/DB01233 (accessed September 17, 2018).
- MeSH. "Antiemetics". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Métoclopramide are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Métoclopramide. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
